RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
By asianet
BENGALURU, India, June 09, 2025 /GLOBE NEWSWIRE – AsiaNet /– RenaissThera Private Limited (“RenaissThera”), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy … Continued